

June 28, 2004

## IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1 (previously presented). A method for treating or preventing a neoplasia disorder in a mammal in need of such treatment or prevention, which method comprises administering to said mammal a therapeutically effective amount of a combination of celecoxib, N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide, and paclitaxel.

2 (original). The method of Claim 1 wherein the combination is administered in a sequential manner.

3 (original). The method of Claim 1 wherein the combination is administered in a substantially simultaneous manner.

~~4-41~~ (cancelled).

42 (original). The method of Claim 1 wherein the neoplasia is selected from the group consisting of lung cancer, breast cancer, gastrointestinal cancer, bladder cancer, head and neck cancer and cervical cancer.

43 (original). The method of Claim 1 wherein the neoplasia is selected from the group consisting of acral lentiginous melanoma, actinic keratoses, adenocarcinoma, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, astrocytic tumors, Bartholin gland carcinoma, basal cell carcinoma, bronchial gland carcinomas, capillary, carcinoids, carcinoma, carcinosarcoma, cavernous, cholangiocarcinoma, chondrosarcoma, choroid plexus papilloma/carcinoma, clear cell carcinoma, cystadenoma, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ependymal, epitheloid, Ewing's sarcoma, fibrolamellar, focal nodular hyperplasia, gastrinoma, germ cell tumors, glioblastoma, glucagonoma, hemangioblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma,

June 28, 2004

hepatic adenomatosis, hepatocellular carcinoma, insulinoma, intraepithelial neoplasia, interepithelial squamous cell neoplasia, invasive squamous cell carcinoma, large cell carcinoma, leiomyosarcoma, lentigo maligna melanomas, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, melanoma, meningeal, mesothelial, metastatic carcinoma, mucoepidermoid carcinoma, neuroblastoma, neuroepithelial adenocarcinoma nodular melanoma, oat cell carcinoma, oligodendroglial, osteosarcoma, pancreatic polypeptide, papillary serous adenocarcinoma, pineal cell, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, small cell carcinoma, soft tissue carcinomas, somatostatin-secreting tumor, squamous carcinoma, squamous cell carcinoma, submesothelial, superficial spreading melanoma, undifferentiated carcinoma, uveal melanoma, verrucous carcinoma, vipoma, well differentiated carcinoma, and Wilm's tumor.

44–114 (cancelled).

115 (previously presented). A therapeutic combination comprising celecoxib, N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide, and paclitaxel.

116–158 (cancelled).

Serial No. 09/868,063  
6794F-000039/US/01 (3167/7Z/US)  
Amendment and Response to Office Action dated June 3, 2004 (Amendment C)  
June 28, 2004

## REMARKS

Following amendment as requested herein, the following claims are pending in the present application: Claims 1–3, 42, 43 and 115.

### Amendment of claims

By the present amendment, Claims 150–158 are cancelled without prejudice. Applicant notes that these claims are not presently under rejection and their cancellation is requested only for the purpose of placing the application in better form for further examination, as explained below.

No new matter is introduced by the present amendment. No changes in inventorship are believed to result from the present amendment.

### Election/restriction requirement under 35 USC §§121 and 372

By the present Office Action, restriction to one of nine groups of claims, relating to different types of cancer, is required.

Applicant appreciates the Examiner's courtesy during a telephone call with the undersigned on June 24, 2004. It was clarified in that call that the present election/restriction requirement, which is very burdensome on Applicant, especially in view of an earlier restriction in the same application, had been precipitated by the addition of new claims 150–158 in a previous amendment (Amendment B). The Examiner indicated that the election/restriction requirement would be withdrawn if claims 150–158 were cancelled.

Applicant accordingly requests withdrawal of the election/restriction requirement in light of cancellation herein of claims 150–158.

Should any issues remain, the Examiner is invited to call the undersigned at the telephone number given below.

Serial No. 09/868,063


6794F-000039/US/01 (3167/7Z/US)

Amendment and Response to Office Action dated June 3, 2004 (Amendment C)

June 28, 2004

Respectfully submitted,

HARNESS, DICKEY & PIERCE, P.L.C.

A handwritten signature in black ink, reading "James C. Forbes". The signature is fluid and cursive, with the first letters of the first and last names being capitalized and prominent.

James C. Forbes  
Agent for Applicant

Reg. No. 39,457

Tel. 847-412-6350

Address correspondence to

Harness, Dickey & Pierce, P.L.C.

7700 Bonhomme, Suite 400

St Louis, MO 63105

Fax: 314-726-7501